Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional

A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults

ClinicalTrials.gov ID: NCT00242879

Public ClinicalTrials.gov record NCT00242879. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen

Study identification

NCT ID
NCT00242879
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
ViiV Healthcare
Industry
Enrollment
130 participants

Conditions and interventions

Interventions

  • Physician determined comparator PI + ritonavir Drug
  • GW640385 + ritonavir Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2005
Primary completion
May 31, 2007
Completion
May 31, 2007
Last update posted
May 29, 2017

2005 – 2007

United States locations

U.S. sites
31
U.S. states
17
U.S. cities
23
Facility City State ZIP Site status
GSK Investigational Site Phoenix Arizona 85006
GSK Investigational Site Bakersfield California 93301
GSK Investigational Site Fountain Valley California 92708
GSK Investigational Site Los Angeles California 90046
GSK Investigational Site San Francisco California 94115
GSK Investigational Site San Francisco California 94121
GSK Investigational Site Denver Colorado 80204
GSK Investigational Site Denver Colorado 80220
GSK Investigational Site Norwalk Connecticut 06851
GSK Investigational Site Washington D.C. District of Columbia 20007
GSK Investigational Site Washington D.C. District of Columbia 20009
GSK Investigational Site Bradenton Florida 34205
GSK Investigational Site Fort Lauderdale Florida 33306
GSK Investigational Site Fort Lauderdale Florida 33308
GSK Investigational Site Fort Lauderdale Florida 33316
GSK Investigational Site Miami Beach Florida 33140
GSK Investigational Site Chicago Illinois 60612-7230
GSK Investigational Site Chicago Illinois 60613
GSK Investigational Site Chicago Illinois 60657
GSK Investigational Site Indianapolis Indiana 46202
GSK Investigational Site Louisville Kentucky 40202
GSK Investigational Site Baltimore Maryland 21201
GSK Investigational Site Boston Massachusetts 02118
GSK Investigational Site Boston Massachusetts 02215
GSK Investigational Site Las Vegas Nevada 89102
GSK Investigational Site Newark New Jersey 7102
GSK Investigational Site Rochester New York 14604
GSK Investigational Site Greenville South Carolina 29605
GSK Investigational Site Dallas Texas 75246
GSK Investigational Site Houston Texas 77027
GSK Investigational Site Hampton Virginia 23666

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00242879, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 29, 2017 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00242879 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →